What is BiomX Inc.'s earnings per share (EPS)?

BiomX Inc. (PHGE) reported diluted earnings per share of $22.19 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BiomX Inc. (PHGE) Financials

PHGE

Ticker history: PHGE became HLSQ (Tessera Defense and Homeland Security Inc.) on 2026-09-11. Earlier news and filings retain their original names and dates. View PHGE history.

FY2025 annual

Revenue Not reported for FY2025

EPS (Diluted) $22.19 YoY not available

Free Cash Flow -$26.4M +28.7% YoY

Operating Cash Flow -$26.4M +28.6% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 19, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PHGE SEC filings page.

This page shows BiomX Inc. (PHGE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PHGE FY2025 2026-10-03

By FY2025, the business had a much smaller balance sheet, continued consuming cash, and depended on financing while liabilities exceeded assets.

Cash-use quality deteriorated structurally rather than through heavy reinvestment: FY2025 operating cash flow of -$26.4M was nearly identical to free cash flow of -$26.4M, while capital expenditures were only $2K. That means the cash requirement primarily reflected ongoing operations, not expansion spending.

Financial capacity narrowed sharply between FY2024 and FY2025: total assets fell from $43.2M to $5.8M, while liabilities remained above assets in FY2025, producing negative equity of -$1.3M. The current ratio also moved below 1.0x, indicating current liabilities exceeded current assets.

External financing remained central to the cash profile. FY2025 financing supplied $13.2M against operating cash outflow of $26.4M, following $38.4M of financing inflow in FY2024; this pattern connects continuing operating cash consumption with repeated balance-sheet funding rather than internally generated cash.

Financial Health Signals

Financial health score not available

BiomX Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$332K

BiomX Inc. generated $332K in revenue in Q2 2026.

Net Income

-$3.8M

YoY+36.3%

BiomX Inc. reported -$3.8M in net income in Q2 2026. This represents an increase of 36.3% from the same quarter a year earlier.

EPS (Diluted)

$0.37

YoY-89.9%

5Y CAGR+4.3%

BiomX Inc. earned $0.37 per diluted share (EPS) in Q2 2026. This represents a decrease of 89.9% from the same quarter a year earlier.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$347K

YoY-97.5%

QoQ-70.3%

5Y CAGR-62.4%

BiomX Inc. held $347K in cash against $247K in long-term debt as of Q2 2026, with $10.2M of liabilities due within a year.

Shares Outstanding

27M

YoY+0.7%

5Y CAGR-1.1%

BiomX Inc. had 27M shares outstanding in Q2 2026. This represents an increase of 0.7% from the same quarter a year earlier.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

29.2%

BiomX Inc.'s gross margin was 29.2% in Q2 2026, indicating the percentage of revenue retained after direct costs.

Return on Equity

-35.4%

YoY-3.9pp

BiomX Inc.'s ROE was -35.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 3.9 percentage points from the same quarter a year earlier.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

None of these metrics is reported for Q2 2026.

PHGE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PHGE quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
R&D Expenses	N/A	$21.3M-13.7%	$24.7M+47.7%	$16.7M+2.8%	$16.2M-28.4%	$22.7M+16.8%	$19.4M+43.9%	$13.5M+47.7%	$9.1M
SG&A Expenses	N/A	$9.6M-18.2%	$11.8M+36.1%	$8.7M-8.5%	$9.5M-16.1%	$11.3M+20.9%	$9.3M+6.9%	$8.7M+159.5%	$3.4M
Operating Income	N/A	N/A	-$44.5M-75.6%	-$25.3M+6.9%	-$27.2M+23.2%	-$35.5M-17.2%	-$30.3M-36.3%	-$22.2M-77.7%	-$12.5M
EBITDA	N/A	N/A	-$42.7M-74.5%	-$24.5M+0.9%	-$24.7M+24.9%	-$32.9M-11.1%	-$29.6M-35.2%	-$21.9M-78.2%	-$12.3M
Interest Expense	N/A	$20K-97.6%	$850K-64.6%	$2.4M+16.2%	$2.1M+196.0%	$699K	N/A	N/A	N/A
Income Tax	N/A	$7K-46.2%	$13K-43.5%	$23K-64.6%	$65K-3.0%	$67K	N/A	$135K	N/A
Net Income	N/A	N/A	-$17.7M+32.3%	-$26.2M+7.6%	-$28.3M+21.8%	-$36.2M-20.4%	-$30.1M-46.3%	-$20.6M-61.7%	-$12.7M
EPS (Basic)	N/A	$22.19-12.5%	$25.37+397.5%	$5.10+436.8%	$0.95-31.7%	$1.39	N/A	N/A	N/A
EPS (Diluted)	—	$22.19	$58.31	$5.10+436.8%	$0.95-31.7%	$1.39	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	2M	757,749	5M-82.8%	30M+14.8%	26M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$332K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$235K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$97K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	$6.1M-15.9%	$5.0M-27.3%	$5.3M+27.9%	N/A	$7.3M+29.0%
SG&A Expenses	$5.4M+122.5%	$1.6M-35.7%	N/A	$2.4M-25.7%	$2.4M-14.5%	$2.5M-6.5%	N/A	$3.2M+50.8%
Operating Income	-$5.4M+27.2%	-$1.3M+83.3%	N/A	-$8.5M+24.6%	-$7.4M+23.6%	-$7.8M-14.3%	N/A	-$11.3M-45.3%
EBITDA	N/A	N/A	N/A	-$7.3M+33.7%	-$7.1M	-$7.5M-14.7%	N/A	-$11.0M-45.3%
Interest Expense	$20K+300.0%	$192K-77.4%	N/A	$5K0.0%	$5K-99.4%	$850K0.0%	N/A	$5K-99.1%
Income Tax	N/A	N/A	N/A	$3K	$2K-60.0%	$1K-80.0%	N/A	N/A
Net Income	-$3.8M+36.3%	N/A	N/A	-$9.2M-195.1%	-$6.0M-235.0%	-$7.7M+55.8%	N/A	$9.6M+222.0%
EPS (Basic)	$0.37-89.9%	$7.38+17.7%	$21.39-14.6%	$0.29+193.5%	$3.66+2714.3%	$6.27+125.5%	$25.05+2992.6%	-$0.31-123.8%
EPS (Diluted)	$0.37-89.9%	$7.38	$21.39	$0.29+193.5%	$3.66	$6.27	$55.86	-$0.31
Diluted Shares (Avg)	10M+525.9%	N/A	N/A	31M+91.6%	2M	23M	N/A	16M

PHGE Balance Sheet

PHGE quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$5.8M-86.6%	$43.2M+72.7%	$25.0M-45.0%	$45.5M-41.6%	$78.0M+10.8%	$70.4M-23.6%	$92.1M+103.2%	$45.3M
Current Assets	$5.6M-72.8%	$20.5M+16.4%	$17.6M-52.2%	$36.9M-44.7%	$66.6M+9.8%	$60.7M-28.2%	$84.5M+111.9%	$39.9M
Cash & Equivalents	$4.4M-74.1%	$16.9M+13.1%	$14.9M-52.4%	$31.3M-49.5%	$62.1M+70.2%	$36.5M-49.5%	$72.3M+739.8%	$8.6M
Short-Term Investments	$0	$0	$0-100.0%	$2.0M	$0-100.0%	$19.9M+98.5%	$10.0M-67.8%	$31.1M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	$801K	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.1M-62.9%	$19.1M-13.0%	$21.9M-10.4%	$24.5M-19.6%	$30.5M+136.2%	$12.9M+68.2%	$7.7M+1315.8%	$541K
Current Liabilities	$6.4M-22.8%	$8.3M-26.0%	$11.2M+40.8%	$7.9M-28.1%	$11.0M+54.2%	$7.2M+15.1%	$6.2M	N/A
Non-Current Liabilities	$706K-93.5%	$10.8M+0.4%	$10.8M-34.9%	$16.6M-14.7%	$19.4M+238.6%	$5.7M+297.8%	$1.4M	N/A
Long-Term Debt	N/A	N/A	$5.4M-49.0%	$10.6M-26.5%	$14.4M+186.4%	$5.0M+487.9%	$856K	N/A
Total Equity	-$1.3M-105.4%	$24.1M+683.8%	$3.1M-85.4%	$21.0M-55.7%	$47.5M-17.3%	$57.5M-32.0%	$84.5M+97.3%	$42.8M
Retained Earnings	-$216.9M-20.0%	-$180.7M-10.9%	-$163.0M-19.1%	-$136.8M	N/A	N/A	N/A	$9K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$28.2M-25.9%	$3.3M-92.9%	$5.8M-86.6%	$26.2M-56.4%	$38.0M-44.5%	$45.7M-44.1%	$43.2M+72.7%	$60.0M+81.4%
Current Assets	$2.4M-85.5%	$3.0M-87.1%	$5.6M-72.8%	$8.9M-68.7%	$16.6M-52.6%	$23.5M-50.0%	$20.5M+16.4%	$28.3M+11.9%
Cash & Equivalents	$347K-97.5%	$1.2M-94.2%	$4.4M-74.1%	$6.9M-70.6%	$14.0M-55.6%	$20.1M-53.2%	$16.9M+13.1%	$23.5M+4.8%
Short-Term Investments	$225K	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$327K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$801K	$801K
Total Liabilities	$17.3M-8.3%	$4.1M-80.5%	$7.1M-62.9%	$15.7M-29.0%	$18.9M-54.1%	$21.2M-76.8%	$19.1M-13.0%	$22.1M-11.3%
Current Liabilities	$10.2M+62.6%	$2.4M-65.1%	$6.4M-22.8%	$5.2M-41.6%	$6.3M-14.3%	$7.0M-34.4%	$8.3M-26.0%	$8.9M-30.0%
Non-Current Liabilities	$383K-97.0%	$1.7M-88.1%	$706K-93.5%	$10.5M-20.4%	$12.6M-62.7%	$14.1M-70.6%	$10.8M+0.4%	$13.1M+8.4%
Long-Term Debt	$247K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$10.9M-43.3%	-$881K-103.6%	-$1.3M-105.4%	$10.5M-72.3%	$19.2M-30.1%	$24.5M+356.7%	$24.1M+683.8%	$37.9M+364.8%
Retained Earnings	-$239.8M-23.4%	-$236.0M-25.3%	-$216.9M-20.0%	-$203.6M-22.5%	-$194.4M-10.6%	-$188.4M-4.5%	-$180.7M-10.9%	-$166.2M-5.5%

Not reported in any period shown, so not listed: Inventory.

PHGE Cash Flow Statement

PHGE quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$18.2M	-$26.4M+28.6%	-$37.0M-73.7%	-$21.3M+26.8%	-$29.1M-5.5%	-$27.6M-12.8%	-$24.4M-39.1%	-$17.6M-55.5%	-$11.3M
Depreciation & Amortization	N/A	$2.9M+62.1%	$1.8M+107.0%	$871K-65.4%	$2.5M-1.8%	$2.6M+293.4%	$652K+105.7%	$317K+51.0%	$210K
Stock-Based Compensation	N/A	$2.1M+13.1%	$1.8M+74.5%	$1.1M-30.7%	$1.5M-52.8%	$3.2M+12.0%	$2.9M+208.1%	$938K-1.4%	$951K
Capital Expenditures	N/A	$2K-93.3%	$30K-40.0%	$50K-55.4%	$112K-97.0%	$3.7M+264.9%	$1.0M-23.1%	$1.3M+857.7%	$137K
Free Cash Flow	N/A	-$26.4M+28.7%	-$37.0M-73.5%	-$21.3M+26.9%	-$29.2M+6.6%	-$31.3M-22.8%	-$25.5M-34.8%	-$18.9M-65.1%	-$11.4M
Investing Cash Flow	-$1.6M	$108K-84.9%	$715K-63.4%	$2.0M+192.6%	-$2.1M-113.0%	$16.2M+249.0%	-$10.9M-155.0%	$19.7M+165.7%	-$30.0M
Financing Cash Flow	$4.8M	$13.2M-65.6%	$38.4M+1223.7%	$2.9M+892.8%	$292K-99.2%	$37.3M+27720.9%	$134K-99.8%	$61.6M+43.0%	$43.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.2M+80.8%	-$5.4M+37.9%	-$4.4M+30.3%	-$7.2M+11.3%	-$6.1M+45.6%	-$8.7M+23.3%	-$6.3M-0.8%	-$8.1M-36.7%
Depreciation & Amortization	N/A	N/A	$1.2M+25.2%	$1.2M+285.4%	$292K	$236K+3.1%	$921K+334.4%	$322K+47.0%
Stock-Based Compensation	$4.0M+473.0%	-$1.9M-392.6%	N/A	$438K-47.2%	$696K+803.9%	$659K+272.3%	N/A	$829K+325.1%
Capital Expenditures	N/A	N/A	$0-100.0%	N/A	N/A	N/A	$11K+57.1%	$10K-68.8%
Free Cash Flow	N/A	N/A	-$4.4M+30.4%	N/A	N/A	N/A	-$6.3M-0.8%	-$8.1M-36.2%
Investing Cash Flow	-$556K-1058.6%	-$996K-2052.9%	$1K+200.0%	-$2K-100.0%	$58K+7.4%	$51K-92.3%	-$1K+83.3%	-$1K+96.9%
Financing Cash Flow	$905K+3220.7%	$2.6M-78.0%	$1.3M+414.3%	$54K	-$29K+85.7%	$11.9M-69.4%	-$398K+69.9%	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PHGE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PHGE quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Return on Equity	N/A	-73.4%+776.0pp	-849.4%-714.8pp	-134.6%-58.4pp	-76.2%-23.9pp	-52.3%-28.0pp	-24.3%+5.4pp	-29.7%
Return on Assets	N/A	-41.0%+63.6pp	-104.6%-42.4pp	-62.2%-15.7pp	-46.5%-3.7pp	-42.8%-20.4pp	-22.3%+5.7pp	-28.1%
Current Ratio	0.87-1.6x	2.48+0.9x	1.58-3.1x	4.65-1.4x	6.03-2.4x	8.47-5.1x	13.58	N/A
Debt-to-Equity	N/A	0.79-1.0x	1.75+1.2x	0.50+0.2x	0.30+0.2x	0.09+0.1x	0.010.0x	0.01

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	29.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1630.7%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-1158.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-35.4%-3.9pp	N/A	N/A	-87.4%-112.9pp	-31.5%-47.8pp	-31.3%	N/A	25.4%+122.4pp
Return on Assets	-13.7%+2.2pp	N/A	N/A	-35.0%-51.1pp	-15.9%-22.4pp	-16.8%+4.4pp	N/A	16.1%+40.0pp
Current Ratio	0.24-2.4x	1.24-2.1x	0.87-1.6x	1.70-1.5x	2.66-2.1x	3.35-1.0x	2.48+0.9x	3.17+1.2x
Debt-to-Equity	0.02-1.0x	N/A	N/A	1.50+0.9x	0.99-0.5x	0.86	0.79-1.0x	0.58-0.3x
Asset Turnover	0.01	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.87), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BiomX Inc. PHGE	FY2025	N/A	N/A	N/A	$5.0M	—
Phio Pharmaceuticals Corp. PHIO	FY2025	N/A	-$8.7M	N/A	$11.4M	—
Adaptimmune Therapeutics plc American ADAP	FY2024	$178.0M	-$70.8M	-39.8%	$14.6M	46/100
BioVie, Inc. BIVI	FY2026	N/A	-$22.1M	N/A	$12.1M	—
Apollomics Inc. APLM	FY2025	$8.5M	-$10.9M	N/A	$62.7M	30/100
Aptorum Group Limited APM	FY2025	N/A	-$1.4M	N/A	$570K	—

Where BiomX Inc. Ranks

Frequently Asked Questions

What is BiomX Inc.'s free cash flow?

BiomX Inc. (PHGE) recorded an outflow of $26.4M in free cash flow during fiscal year 2025. This represents a 28.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is BiomX Inc.'s operating cash flow?

BiomX Inc. (PHGE) recorded an outflow of $26.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are BiomX Inc.'s total assets?

BiomX Inc. (PHGE) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are BiomX Inc.'s capital expenditures?

BiomX Inc. (PHGE) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does BiomX Inc. spend on research and development?

BiomX Inc. (PHGE) invested $21.3M in research and development during fiscal year 2025.

How many shares does BiomX Inc. have outstanding?

BiomX Inc. (PHGE) had 2M shares outstanding as of fiscal year 2025.

What is BiomX Inc.'s current ratio?

BiomX Inc. (PHGE) had a current ratio of 0.87 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

How does BiomX Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, BiomX Inc. (PHGE) held $4.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $26.4M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is BiomX Inc.'s debt-to-equity ratio negative or not reported?

BiomX Inc. (PHGE) has negative shareholder equity of -$1.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.